A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Condition: Respiratory DisordersInterventions: Biological: NTHI vaccine GSK2838500A (formulation 1); Biological: NTHI vaccine GSK2838501A (formulation 2); Biological: NTHI vaccine GSK2838502A (formulation 3); Biological: NTHI vaccine GSK2838503A (formulation 4); Biological: NTHI vaccine GSK2838504A (formulation 5); Biological: NTHI vaccine GSK2838505A (formulation 6); Biological: NTHI vaccine GSK2838508A (formulation 7); Biological: NTHI vaccine GSK2838509A (formulation 8); Drug: Placebo comparatorSponsor: GlaxoSmithKlineCompleted - verified June 2014

http://clinicaltrials.gov/ct2/show/NCT01678677?lup_s=08%2F21%2F2014&lup_d=30

Source: ClinicalTrials.gov - August 23, 2012 Category: Research Source Type: clinical trials